INIFY — INIFY Laboratories AB Share Price
Last trade - 00:00- NOK666.34m
- NOK597.27m
- SEK22.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.97 | ||
| Price to Tang. Book | 5 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 30.3 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -54.4% | ||
| Return on Equity | -62.46% | ||
| Operating Margin | -370.27% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | 1.19 | 13.13 | 22.01 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
INIFY Laboratories AB is a Sweden-based medical research company that provides cancer diagnostics through laboratory services within pathology. The Company uses a fully digital, standardized and Artificial Intelligence (AI)- supported workflow to optimize quality and response times, initially within prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. INIFY Laboratories' laboratory in Solna, Sweden is intended to provide two types of analyses of prostate Biopsy Specimens to clients: Full pathology Report signed by an INIFY subspecialized pathologist and Whole Slide Images (WSI) generation and result of Pathology Decision Support Tool (PDST) analysis only. The Company origins from ContextVision.
Directors
- Lars Sanden CHM (61)
- Knut Ingvar DRC (68)
- Magne Jordanger DRC (71)
- Fredrik Palm CEO
- Ann-Charlotte Linderoth CFO
- Arto Jarvinen CTO
- Magnus Aurell OTH
- Johanna Karling OTH (60)
- Emelie Edvigsson OTH
- Last Annual
- December 31st, 2025
- Last Interim
- September 30th, 2026
- Incorporated
- November 10th, 2021
- Public Since
- June 20th, 2022
- No. of Employees
- 38
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Oslo Stock Exchange
- Shares in Issue
- 107,474,845
- Address
- Scheeles vag 3, SOLNA, 171 65
- Web
- https://www.inify.com/
- Phone
- +46 8267330
- Auditors
- Grant Thornton Sweden AB
Latest News for INIFY
Upcoming Events for INIFY
Similar to INIFY
Codelab Capital AS
Oslo Stock Exchange
ContextVision AB
Oslo Stock Exchange
Gentian Diagnostics ASA
Oslo Stock Exchange
Medistim ASA
Oslo Stock Exchange
Nordhealth AS
Oslo Stock Exchange
FAQ
As of Today at 20:20 UTC, shares in INIFY Laboratories AB are trading at NOK6.20. This share price information is delayed by 15 minutes.
Shares in INIFY Laboratories AB last closed at NOK6.20 and the price had moved by +12.73% over the past 365 days. In terms of relative price strength the INIFY Laboratories AB share price has underperformed the FTSE Global All Cap Index by -1.84% over the past year.
There is no consensus recommendation for this security.
Find out moreINIFY Laboratories AB does not currently pay a dividend.
INIFY Laboratories AB does not currently pay a dividend.
INIFY Laboratories AB does not currently pay a dividend.
To buy shares in INIFY Laboratories AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of NOK6.20, shares in INIFY Laboratories AB had a market capitalisation of NOK666.34m.
Here are the trading details for INIFY Laboratories AB:
- Country of listing: Norway
- Exchange: OSL
- Ticker Symbol: INIFY
Based on an overall assessment of its quality, value and momentum INIFY Laboratories AB is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like INIFY Laboratories AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +47.21%.
As of the last closing price of NOK6.20, shares in INIFY Laboratories AB were trading +17.51% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The INIFY Laboratories AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at NOK6.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
INIFY Laboratories AB's management team is headed by:
- Lars Sanden - CHM
- Knut Ingvar - DRC
- Magne Jordanger - DRC
- Fredrik Palm - CEO
- Ann-Charlotte Linderoth - CFO
- Arto Jarvinen - CTO
- Magnus Aurell - OTH
- Johanna Karling - OTH
- Emelie Edvigsson - OTH